Par Pharma, Sanofi-Aventis Settle Eloxatin Patent Dispute
Eloxatin, combined with the chemotherapy regimen of 5-FU/LV, is approved by the FDA for the treatment of advanced colorectal cancer (cancer of the colon and/or rectum). Sanofi, under
Daiichi Sankyo and Merck & Co (MSD) have voluntarily withdrawn their biologics license application (BLA) for ifinatamab deruxtecan, aimed at treating adult patients with extensive-stage small cell lung cancer (ES-SCLC) following disease progression after platinum-based chemotherapy.
In the published study, Gilles Blancho and colleagues from the Institute of Transplantation – Urology – Nephrology (ITUN) in Nantes, France, have demonstrated that Pharming’s rhC1INH prevented AMR
Ardea Biosciences said that in the 28-day, randomised, double-blind, placebo-controlled, dose-escalation study, 123 gout patients with hyperuricemia, received 200mg once-daily (qd) RDEA594, 400mg qd RDEA594, 600mg qd RDEA594